NCT05184530View on ClinicalTrials.gov

In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction

CompletedOBSERVATIONAL
Enrollment

7,556

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2021

Conditions
Coronary Disease
Interventions
DRUG

Evolocumab 140 MG/ML

140 mg per two weeks, subcutaneous injection

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER

NCT05184530 - In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter